BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 2412917)

  • 1. Mapping of type 1 poliovirus neutralization epitopes.
    Blondel B; Crainic R; Dufraisse G; Candréa A; Horaud F
    Dev Biol Stand; 1985; 60():337-42. PubMed ID: 2412917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigenic modification of attenuated Sabin type 1 poliovirus by in vitro passages at supraoptimal temperatures.
    Crainic R; Blondel B; Candréa A; Dufraisse G; Horaud F
    Dev Biol Stand; 1985; 60():343-7. PubMed ID: 2995173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization epitope patterns of poliovirus strains isolated from paralytic cases.
    Crainic R; Blondel B; Aubert-Combiescu A; Beytout D; Couillin P; Candrea A; Boué A; Horaud F
    Dev Biol Stand; 1984; 57():165-70. PubMed ID: 6084607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of monoclonal antibodies prepared with Sabin vaccine viruses for the characterization of poliovirus strains isolated in Canada.
    Wachmann B; Henning D; Armstrong R; Boucher DW; Contreras G; Furesz J
    Dev Biol Stand; 1984; 57():141-9. PubMed ID: 6084605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains.
    Sawyer LA; McInnis J; Albrecht P
    Biologicals; 1993 Jun; 21(2):169-77. PubMed ID: 8297601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of monoclonal antibodies for the identification of the antigenic site for poliovirus neutralization.
    Minor PD; Schild GC; Evans D; Ferguson M; Almond J
    Dev Biol Stand; 1984; 57():171-5. PubMed ID: 6084608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains.
    Tano Y; Shimizu H; Martin J; Nishimura Y; Simizu B; Miyamura T
    Vaccine; 2007 Oct; 25(41):7041-6. PubMed ID: 17825459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic sites of poliovirus type 3 eliciting IgA monoclonal antibodies in orally immunized mice.
    Buttinelli G; Ruggeri FM; Marturano J; Novello F; Donati V; Fiore L
    Virology; 2001 Mar; 281(2):265-71. PubMed ID: 11277698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site.
    Blondel B; Crainic R; Fichot O; Dufraisse G; Candrea A; Diamond D; Girard M; Horaud F
    J Virol; 1986 Jan; 57(1):81-90. PubMed ID: 2416957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenic variation of poliovirus studied by means of monoclonal antibodies.
    Crainic R; Blondel B; Horaud F
    Rev Infect Dis; 1984; 6 Suppl 2():S535-9. PubMed ID: 6204369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of the antigenic variation in poliovirus type 1. Selection and analysis of variant strains with monoclonal antibodies by neutralization.
    Thibodeau L; Lacroix M; Lecomte J; Fauvel M
    Dev Biol Stand; 1984; 57():157-63. PubMed ID: 6084606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic sites on type 2 poliovirus.
    Patel V; Ferguson M; Minor PD
    Virology; 1993 Jan; 192(1):361-4. PubMed ID: 7685967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodies.
    Fiore L; Ridolfi B; Genovese D; Buttinelli G; Lucioli S; Lahm A; Ruggeri FM
    J Virol; 1997 Sep; 71(9):6905-12. PubMed ID: 9261417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.
    Minor PD; Evans DM; Ferguson M; Schild GC; Westrop G; Almond JW
    J Gen Virol; 1985 May; 66 ( Pt 5)():1159-65. PubMed ID: 2582084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method.
    Rezapkin G; Martin J; Chumakov K
    Biologicals; 2005 Mar; 33(1):29-39. PubMed ID: 15713554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural variation of poliovirus neutralization epitopes.
    Crainic R; Couillin P; Blondel B; Cabau N; Boué A; Horodniceanu F
    Infect Immun; 1983 Sep; 41(3):1217-25. PubMed ID: 6193066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A monoclonal antibody panel for the intratypic differentiation of type-2 polioviruses].
    Shyrobokov VP; Nikolaienko IV; Kopanytsia LV; Solohub VK; Ivanova OIe
    Mikrobiol Z; 1997; 59(6):27-36. PubMed ID: 9511373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies to polioviruses. Production of specific monoclonal antibodies to the Sabin vaccine strains.
    Osterhaus AD; van Wezel AL; van Steenis B; Drost GA; Hazendonk TG
    Intervirology; 1981; 16(4):218-24. PubMed ID: 6177658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan.
    Horie H; Yoshida H; Matsuura K; Miyazawa M; Wakabayashi K; Nomoto A; Hashizume S
    J Med Virol; 2002 Nov; 68(3):445-51. PubMed ID: 12226835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen chimaeras of poliovirus as potential new vaccines.
    Burke KL; Dunn G; Ferguson M; Minor PD; Almond JW
    Nature; 1988 Mar; 332(6159):81-2. PubMed ID: 2450279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.